Dyno Therapeutics develops technologies for safe, efficient and targeted in vivo delivery of new gene therapies and genome editing therapies. Our data-driven approach combines next-generation DNA synthesis of millions of AAV capsids with high-throughput sequencing and machine learning.
- Eric Kelsic, PhD Co-founder and CEO
- Alan Crane Co-founder and Executive Chairman
- Adrian Veres, PhD Co-founder, Advisor
- Sam Sinai, PhD Co-founder and Lead ML Scientist
- George Church, PhD Co-founder